Evidence map›Paper›PMID 42471435›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026

Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.

James J Gattuso, Ahmed Kamal, Jennyfer M Payet, Kato Havaux, Jenna Hendey, Bilgenur Bezcioglu, Zoe J Phelan, Maddy Orchard, Divyesh Bhanot, Matthew W Hale and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

James J GattusoFlorey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-0543-8728
Ahmed KamalFlorey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Jennyfer M PayetDepartment of Psychology, Counselling and Therapy, School of Psychology and Public Health, La Trobe University, Melbourne, VIC, Australia.
Kato HavauxFlorey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Jenna HendeyFlorey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Bilgenur BezciogluFlorey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Zoe J PhelanDepartment of Psychology, Counselling and Therapy, School of Psychology and Public Health, La Trobe University, Melbourne, VIC, Australia.
Maddy OrchardFlorey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Divyesh BhanotFlorey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Matthew W HaleDepartment of Psychology, Counselling and Therapy, School of Psychology and Public Health, La Trobe University, Melbourne, VIC, Australia.
Anthony J HannanFlorey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia. anthony.hannan@florey.edu.au.ORCID http://orcid.org/0000-0001-7532-8922
Thibault RenoirFlorey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia. tibo.renoir@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psilocybin is a serotonergic psychedelic drug with emerging therapeutic applications, yet its actions under glutamatergic dysfunction, and relevance to schizophrenia and associated psychiatric disorders, remain unclear. We examined the acute and long-lasting effects of psilocybin (1 mg/kg, intraperitoneal) on behavioral and neural outcomes in the metabotropic glutamate receptor 5 (mGlu5) knockout (KO) mouse model of schizophrenia. The mGlu5 KO mice displayed psilocybin-induced hyperlocomotion, whereas wild-type (WT) mice did not. Additionally, male mGlu5 KO mice showed an amplified psilocybin-induced head-twitch response (HTR) compared with WT males, consistent with sex-dependent enhancement of 5-HT

Indexed as

HallucinogensReceptor, Metabotropic Glutamate 5SchizophreniaSensory GatingSex CharacteristicsAnimalsDisease Models, AnimalFemaleMaleMiceMice, Inbred C57BLMice, KnockoutMotor ActivityPrepulse InhibitionProto-Oncogene Proteins c-fosReflex, StartleGrm5 protein, mouseHallucinogensProto-Oncogene Proteins c-fosReceptor, Metabotropic Glutamate 5

Identifiers

PMID42471435
PMCPMC13598084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.